Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report documents a successful treatment of alopecia areata using Ayurvedic management, suggesting that Ayurveda could help restore balance and promote hair regrowth in this autoimmune condition.

In this report, trichoscopy was highlighted as a valuable tool for diagnosing temporal triangular alopecia in children due to its ability to reveal distinctive patterns that differentiate it from similar conditions like alopecia areata, eliminating the need for invasive biopsy.

This study found that nearly 40% of patients with severe alopecia areata who showed eyebrow or eyelash regrowth on baricitinib 4 mg achieved significant scalp hair regrowth by the second year of treatment.

This article is a letter to the editor discussing potential therapeutic synergy between a wig-fixing device and tofacitinib for treating alopecia areata but reports no new clinical results.

This study found that oral tofacitinib led to variable hair regrowth in patients with resistant alopecia areata, implying that longer treatment durations may be needed to fully assess its effectiveness.

In this case study, a patient with refractory oral lichen planus experienced marked improvement within one month of daily treatment with baricitinib, contributing to the evidence supporting the use of JAK inhibitors for lichen planus.

This study found that patients with alopecia areata had similar total health care costs as those with atopic dermatitis, despite having fewer comorbidities and prescription medications overall.

This study found that alopecia areata significantly impacts patients' quality of life irrespective of hair loss severity, and concluded that the newer assessment tools AAPPO and AASIS better capture this impact compared to the traditional SALT measure.

This study reported that allethrin caused dose-dependent toxico-pathological effects, including decreased feed intake, body weight, and blood parameters, and organ damage in adult male albino rats.

This study examined the safety and efficacy of dupilumab in adolescents with moderate-to-severe atopic dermatitis, finding that it was well tolerated and significantly improved symptoms over 52 weeks, with its safety profile similar to that in adults.

This study aims to assess the real-world effectiveness of baricitinib, a JAK inhibitor, for promoting regrowth of nasal, genital, and beard hair in patients with severe alopecia areata, expanding on findings from the BRAVE-AA clinical trial. Results are not reported.

This study discusses the impact of alopecia on individuals' appearance and psychological well-being, highlighting how factors like genetics and lifestyle influence hair loss, and explores traditional Ayurvedic approaches for managing and promoting hair regrowth.

This case report highlights a 31-year-old male with Adult Onset Still Disease, whose symptoms, including high fever, responded only to pulse-therapy with Methylprednisolone after failing to improve with usual treatments.

A man developed alopecia areata after starting cancer treatment with vandetanib.

This review found that oral JAK inhibitors, used off-label in various inflammatory skin disorders, often resulted in rapid and sustained clinical improvements with acceptable safety over several months, although the evidence is drawn from case-based reports.

Ritlecitinib works well and is safe for treating alopecia areata.

This study found that long-term exposure to high pH extends root hair elongation by altering actin filament arrangements and vesicle trafficking, but disrupting ADF8/11 function shortens root hairs by affecting these processes.

This article reviews antibody drug conjugates for cancer treatment, describing their mechanism, recent approvals, and ongoing research efforts, but reports no new clinical results.

This study found that using deep plane fixation during scalp surgeries significantly reduced closure tension and allowed for increased tissue excision compared to standard techniques without fixation.

This review highlights Ritlecitinib as a promising new oral treatment for Alopecia Areata, emphasizing its targeted action and potential efficacy, especially in adults and adolescents, though it notes the need for further real-world effectiveness and long-term safety studies.

This paper highlights a case where a 2-year-old boy with temporal triangular alopecia was initially misdiagnosed with alopecia areata, emphasizing the importance of dermoscopy for accurate early diagnosis to avoid unnecessary treatments.

In this study, tofacitinib showed a mixed response in treating refractory alopecia areata, with some patients experiencing complete or partial hair regrowth and others showing no response, particularly those with alopecia universalis.

This study discusses the immune dysregulation observed in individuals with Down syndrome, highlighting their increased risk for autoimmune skin conditions, but does not yet clarify the molecular mechanisms behind this profile.

This study found that oral Janus kinase inhibitors were effective in treating alopecia areata, with a clinical response rate of 48.3%, though further research is needed to assess long-term effects.

Baricitinib effectively promotes beard regrowth in most men with alopecia areata universalis.

This article discusses alopecia areata, highlighting its autoimmune nature and the lack of FDA-approved treatments, without providing new research findings.

In this study, a 24-year-old patient with severe alopecia areata showed an excellent clinical response to the JAK inhibitor tofacitinib after one month, following unsuccessful previous treatments.

Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.

This study reported that heterozygosity for FHIT affects mice's susceptibility to spontaneous alopecia areata and to certain preneoplastic lesions induced by benzo[a]pyrene, but does not change how they respond to budesonide and N-acetyl-L-cysteine.